desipramine and Low Back Ache studies

Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.
desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.

Research Excerpts

Excerpt	Relevance	Reference
"This clinical trial evaluated the independent and combined effects of a tricyclic antidepressant (desipramine) and cognitive behavioral therapy (CBT) for chronic back pain relative to an active placebo treatment."	9.34	A randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain. ( Atkinson, JH; Capparelli, EV; Chircop-Rollick, T; D'Andrea, J; Funk, SD; Garfin, S; Gould, HM; Patel, SM; Penzien, DB; Rutledge, T; Slater, M; Wallace, M; Weickgenanta, AL, 2020)
"This clinical trial evaluated the independent and combined effects of a tricyclic antidepressant (desipramine) and cognitive behavioral therapy (CBT) for chronic back pain relative to an active placebo treatment."	5.34	A randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain. ( Atkinson, JH; Capparelli, EV; Chircop-Rollick, T; D'Andrea, J; Funk, SD; Garfin, S; Gould, HM; Patel, SM; Penzien, DB; Rutledge, T; Slater, M; Wallace, M; Weickgenanta, AL, 2020)

Research

Studies (1)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Intent-toTreat Analysis of Descriptor Differential Scale (DDS) of Pain Intensity

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors	Studies
Gould, HM	1
Atkinson, JH	1
Chircop-Rollick, T	1
D'Andrea, J	1
Garfin, S	1
Patel, SM	1
Funk, SD	1
Capparelli, EV	1
Penzien, DB	1
Wallace, M	1
Weickgenanta, AL	1
Slater, M	1
Rutledge, T	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Efficacy of Antidepressants in Chronic Back Pain[NCT00964886]	Phase 2	142 participants (Actual)	Interventional	2010-01-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

"The DDS is self-report measure of current pain intensity of chronic back pain. Participants rate pain on a 20 point scale as being greater or less intense relative to 12 adjectival descriptor words which serve as anchors (eg, greater or less than faint, moderate, strong). Scores range from 0 to 20 with higher scores indicating higher pain intensity. The analysis evaluated the 'as randomized' sample at 12 weeks after baseline or last observation carried forward, after co-varying for baseline (pre-treatment) values." (NCT00964886)
Timeframe: 12 weeks after baseline (or last observation carried forward)

Roland and Morris Disability Questionnaire

Intervention	units on a scale (Mean)
Arm 1 + Arm 3	8.3
Arm 2 + Arm 4	8.1
Arm 2 + Arm 3	8.0
Arm 1 + Arm 4	8.4

"This questionnaire measures disability in everyday function due to back pain. It is a 24-item checklist asking patients to endorse whether or not back pain limits activities they normally do (eg, I stay at home most of the time because of my back). Scores range from 0 to 24, with higher scores indicating greater disability in everyday function due to back pain. The analysis evaluated the 'as randomized' sample at 12 weeks after baseline, after co-varying for baseline (pre-treatment) values." (NCT00964886)
Timeframe: 12 weeks after baseline (or last observation carried forward)